A5102917267- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Systemic Sclerosis and Related Diseases
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Eicosanoids and Hypertension Pharmacology
- Cytomegalovirus and herpesvirus research
- Diabetes and associated disorders
- Salivary Gland Disorders and Functions
- T-cell and B-cell Immunology
- Hemoglobinopathies and Related Disorders
- Chemokine receptors and signaling
- Bladder and Urothelial Cancer Treatments
- Immunotherapy and Immune Responses
- Head and Neck Cancer Studies
- Erythropoietin and Anemia Treatment
- Diet and metabolism studies
- Blood groups and transfusion
- Pediatric health and respiratory diseases
- CAR-T cell therapy research
- Multiple and Secondary Primary Cancers
- Cytokine Signaling Pathways and Interactions
- Adipose Tissue and Metabolism
Institut Gustave Roussy
2021-2024
Centre National de la Recherche Scientifique
2021-2024
Inserm
2021-2024
Université Paris-Saclay
2021
Universidade Estadual Paulista (Unesp)
1987-1988
Circulating senescent CD8+ T (T8sen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance immunotherapy in patients with advanced non-small cell lung cancer (aNSCLC). We aimed better characterize T8sen determine which factors were their accumulation aNSCLC. higher expression SA-βgal the transcription factor T-bet, confirming status. Using whole virome profiling, cytomegalovirus (CMV) was only virus T8sen. CMV...
Immunotherapy is standard of care in mRCC but tools for patients' selection are lacking. The NIVOREN GETUG-AFU 26 study nivolumab included a translational program with assessment circulating cytokines. We found IL-8 to be associated overall survival (Carril-Ajuria et al. ASCO. 2022). Here, we aimed evaluate the association between and immune landscape, including both tissue-based assessments. Out 720 pts treated nivo within study, 353 available cytokine quantification were analysis....
4552 Background: The NIVOREN GETUG-AFU 26 study launched a translational research program to quantify baseline circulating soluble factors levels and correlate them with outcomes nivolumab in mRCC pts. We previously identified on training set (n = 80, 40 responders/40 progressors) several significantly associated worse overall survival (OS), progression-free (PFS) response (IL-8 VEGF), or OS only (IL-6, IL-7) (Carril-Ajuria et al. ASCO GU. 2022). Our aim was confirm these findings using an...
<h3>Background:</h3> Immunosenescence (IS) is a global remodeling of immune functions that has been first described with aging. It also associated infectious diseases and cancer. Circulating immunosenescent T-cells are observed in more than 25% the patients advanced non–small cell lung correlates lack benefit from checkpoint inhibitors. The mechanisms leading to IS still only partially understood poorly Immune mediated inflammatory (IMIDs). Chronic inflammation potential driver....
724 Background: The NIVOREN GETUG-AFU 26 study launched a translational research program to quantify baseline circulating soluble factors levels and correlate them with outcomes irAEs in mRCC pts treated nivolumab. We previously identified (training-set = 80 pts, validation-set= 233 pts) several associated overall survival (IL-6, IL-8, VEGF, BAFF, CXCL13) (Carril-Ajuria et al. ASCO. 2022). Our aim was evaluate the association between of presence all grade severe irAEs. Methods: 720 patients...
379 Background: The NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with RCC a “real world setting”. A translational research program was launched to quantify baseline cytokine levels correlate them outcomes nivolumab. Methods: Extreme responder (pts) treated as part the phase II were included this TRAINING cohort. panel 14 different plasma cytokines proteins (VEGF, VCAM-1, IL-6, IL-7, IL-8, IL-10, APRIL, BAFF, 4-1BB, BCA, SDF-1, MDC, IFN-gamma TNF-alpha)...